Heraldnet.com
TUESDAY, DECEMBER 2, 2008 11:16 pm
LocalNorthwestNation & WorldPoliticsSpecial ReportsPhotosColumnistsMultimedia 
Blog
Michelle Dunlop
Airline merger news and 'non-passenger' fees
Your town news
Steve Tytler
Steve Tytler answers your questions about real estate.
•Latest: Welcome mat out for zero-down VA loans
 
WEEK IN REVIEW
Monday


Crops attract snow geese; hunts control field-d...
County budget cuts hit courts, will affect cities
Man sold Lowe's gift cards from stolen goods, p...
Sunday


Fighting foreclosure: How one couple got caught...
Monroe man's family remembers a life devoted to...
155-year boys club comes to an end
Saturday
How to avoid holiday thieves
Burn ban orders will have new teeth
Get a flu shot now, officials urge
Friday


A community in limbo
Ideas arise on housing sex offenders
Turnout for historic election breaks county and...
Thursday


Ways to Give: Where you can make a difference
Ways to give: Charities hit hard from both sides
County Council cuts deeply from most staff exce...
Wednesday


Cancer survivor is again living the life of a t...
Tulalip school is grieving once more
Faulty part bogs down Boeing's jet lines
Tuesday


'We are devastated' by loss of two boys, family...
A scramble to shave $1.8 million from county bu...
Arlington about to add land; buildup could follow
 

ADVERTISEMENT

Business   Print This Article  Email This Page  Subscribe Now! facebook digg reddit del.icio.us fark stumble

 
ADVERTISEMENT

 
CONTACT THE HERALD
Mike Benbow, Business Editor
benbow@heraldnet.com
 
Published: Tuesday, August 5, 2008

Biotech firm cuts president, 22 other jobs

Bothell-based MDRNA Inc. cut nearly 150 jobs since fall as it tries to reinvent itself.

BOTHELL -- MDRNA Inc. is laying off 23 more employees, including its president, as the biotechnology firm formerly known as Nastech Pharmaceuticals tries to reinvent itself.

After the job cuts, which are effective immediately, Bothell-based MDRNA will employ 55 people full time by the end of this month. Since last fall, MDRNA has slashed nearly 150 positions.

In the second quarter, the company lost more than $14 million, or 48 cents a share, up from a loss of $12 million in the year-ago period. The company's revenue totaled $700,000, down sharply from nearly $5 million in the same quarter of 2007.

MDRNA, which ended the second quarter with just less than $20 million in cash and short-term investments, will take a nearly $2 million charge to cover severance and other costs related to the layoffs.

Once focused on nasally inhaled medications, MDRNA shifted its name and focus after a series of setbacks in its drug development programs. The biggest blow was Procter & Gamble Pharmaceuticals' termination of an agreement to help the company develop a nasal spray to treat osteoporosis. The drug development agreement potentially was worth more than $500 million.

In the months since losing that agreement, MDRNA's shares have lost more than 90 percent of their value.

That tailspin resulted in the company's decision to turn its research focus from nasally inhaled drugs to RNA interference, a cellular mechanism that can halt proteins vital to expanding viruses in the body. The company hopes it can use RNA interference to develop treatments for a variety of cancers and other conditions.

That new focus, the company's new name and other changes were announced in early June. Michael French, who took over as chief executive officer at that time, said the transition continues. With that in mind, most of the 23 people being laid off are from the company's nasal development programs. Also included are the company's president, Gordon Brandt; its chief business officer; and the chief scientific officer in charge of nasal delivery programs.

French said MDRNA will not start any new research on nasally inhaled medications. Instead, 60 percent of the remaining work force will be focused on research and development related to RNA interference, he said. By 2010, the company may be ready to begin clinical trials on such new drugs.

The company still hopes, however, to recoup some of its years of work and investment into nasally delivered drugs, Brandt said.

"We believe that our intranasal assets have significant value," Brandt said, adding that MDRNA has received several inquiries from firms interested in acquiring those drug development programs. "We hope to be able to announce one or more such transactions soon."



Reporter Eric Fetters: 425-339-3453 or fetters@heraldnet.com.

1. SPEEA to vote today on Boeing contract
2. Man sold Lowe's gift cards from stolen goods, police allege
3. County budget cuts hit courts, will affect cities
4. Crops attract snow geese; hunts control field-damaging flocks
5. Barry Manilow to play Everett
6. Camano Island pair arrested with list of stolen credit card numbers
7. Gambling's growth prompts casino dealer school in Everett
8. Sultan financial errors detailed
9. Reardon can take days without pay
10. Silvertips take one (or two, or three, or more ...) for the team
Enterprise Newspaper Snohomish County Business Journal
Restaurant is a 'dream come true' for owner
Council unanimously adopts 2009 budget
Colleges brace for massive cuts
Was burglary suspect burglarized?
Food banks facing hard times
Council member resigns, heading to D.C.
Edmonds closes aid car loophole
Wildcats head to state semifinals
Thanksgiving served with an outpouring of generosity
The Enterprise Online Newspaper

TODAY'S TOP JOBS
 View All Top Jobs 
Top Cars
Top Homes


ADVERTISEMENT